MACK - メリマック・ファ―マシュ―ティカルズ (Merrimack Pharmaceuticals Inc.)

MACKのニュース

   Merrimack Pharmaceuticals GAAP EPS of $0.02  2023/05/04 21:47:44 Seeking Alpha
Merrimack Pharmaceuticals press release (MACK): Q1 GAAP EPS of $0.02.Merrimack reported a gain on the sale of assets for the first quarter ended March 31, 2023, of $139…
   Merrimack Pharmaceuticals GAAP EPS of -$0.11  2023/03/09 21:58:50 Seeking Alpha
Merrimack Pharmaceuticals press release (MACK): FY GAAP EPS of -$0.11.As of December 31, 2022, Merrimack had cash and cash equivalents of $19.4 million, compared to $14.2 million as…
   Merrimack Reports Full Year 2022 Financial Results  2023/03/09 21:40:00 Merrimack Pharmaceuticals
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Mar. 9, 2023-- Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) (“Merrimack” or the “Company”) today announced its full year 2022 financial results for the period ended December 31, 2022 . “We are encouraged by the results of the NAPOLI 3 trial as reported by Ipsen
   Current Volume Sizzlers: GeoVax Labs, Inc. (NASDAQ:GOVX -13.51%), Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK -0.44%)  2023/01/26 17:06:10 Stock Equity
GOVX has seen its SMA50 which is now 34.08%. In looking the SMA 200 we see that the stock has seen a -16.11%. MACK has seen its SMA50 which is … The post Current Volume Sizzlers: GeoVax Labs, Inc. (NASDAQ:GOVX -13.51%), Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK -0.44%) appeared first on Stocks Equity .
   Merrimack Still Has Significant Arbitrage Potential (NASDAQ:MACK)  2023/01/04 15:33:10 Seeking Alpha
In Dec. 2022, Merrimack got positive clinical results for its Phase III clinical trial of Onivyde in first line pancreatic cancer. See why we remain bullish on MACK stock.
   Merrimack Pharmaceuticals Stock: Out For Now (MACK)  2022/08/08 20:16:30 Seeking Alpha
Merrimack''s partner Ipsen had a recent failure of the applications of its drug ONIVYDE. Read more to find out what this means for MACK stock.
   Merrimack Pharmaceuticals GAAP EPS of -$0.04 (NASDAQ:MACK)  2022/08/04 21:12:28 Seeking Alpha
Merrimack Pharmaceuticals press release (MACK): Q2 GAAP EPS of -$0.04.As of June 30, 2022, Merrimack had cash and cash equivalents of $13.4 million, compared to $14.2 million as…
   Merrimack Pharma-Ipsen''s Cancer Drug Fails In Overall Survival Measure  2022/08/03 15:49:40 Benzinga
Merrimack Pharmaceuticals Inc''s (NASDAQ: MACK ) partner announced that Ipsen SA (OTC: IPSEY ) reported a primary analysis of the results of the Phase 3 trial of Onivyde (irinotecan liposomal injection)for second-line small cell lung cancer (SCLC). The study did not meet the primary endpoint of overall survival in patients treated with Onivyde … Full story available on Benzinga.com
   Merrimack: Ipsen''s Phase 3 Trial Of Onivyde Fails To Meet Primary Endpoint  2022/08/03 13:14:32 Nasdaq
(RTTNews) - Merrimack Pharmaceuticals, Inc. (MACK) said Ipsen has reported its primary analysis of the results of phase 3 trial of Onivyde as a treatment of second line small cell lung cancer. The primary endpoint OS was not met in patients treated with Onivyde versus topotecan.
   Merrimack Provides Ipsen Report of Results From Phase III RESILIENT Trial Evaluating Onivyde® in Second-Line Monotherapy for Small Cell Lung Cancer  2022/08/03 12:30:00 Merrimack Pharmaceuticals
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Aug. 3, 2022-- Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) [(“Merrimack” or the “Company”)] announced that Ipsen, SA (“Ipsen”) has issued a press release today reporting its primary analysis of the results of its Phase 3 trial of Onivyde® (irinotecan liposomal
   Merrimack Pharmaceuticals GAAP EPS of -$0.01  2022/05/05 20:49:44 Seeking Alpha
Merrimack Pharmaceuticals press release (MACK): Q1 GAAP EPS of -$0.01.“During the first quarter of 2022 we continued to see reductions in our operating expenses and were able to close…
   Merrimack Reports First Quarter 2022 Financial Results  2022/05/05 20:30:00 Merrimack Pharmaceuticals
CAMBRIDGE, Mass. --(BUSINESS WIRE)--May 5, 2022-- Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) [(“Merrimack” or the “Company”)] today announced its first quarter 2022 financial results for the period ended March 31, 2022 . “During the first quarter of 2022 we continued to see reductions in our
   Merrimack Pharmaceuticals reports FY results (NASDAQ:MACK)  2022/03/09 22:17:18 Seeking Alpha
Merrimack Pharmaceuticals press release (MACK): FY GAAP EPS of -$0.18.As of December 31, 2021, Merrimack had cash and cash equivalents and investments of $14.2 million, compared to…
   Merrimack Reports Full Year 2021 Financial Results  2022/03/09 21:30:00 Merrimack Pharmaceuticals
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Mar. 9, 2022-- Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) (“Merrimack” or the “Company”) today announced its full year 2021 financial results for the period ended December 31, 2021 . “During 2021 we have continued to reduce our operating expenses and remain
   Mack® LR Electric Model Now in Serial Production at Lehigh Valley Operations  2021/12/20 21:47:00 Kwhen Finance

calendar